Literature DB >> 17351903

Risk of second cancer after chronic lymphocytic leukemia.

Claudia Schöllkopf1, Ditte Rosendahl, Klaus Rostgaard, Christian Pipper, Henrik Hjalgrim.   

Abstract

Smoking is not considered a risk factor for chronic lymphocytic leukemia (CLL) yet increased lung cancer risk has been reported for these patients. Little data exist on the temporal variation in lung cancer risk after CLL, or its histological composition. We investigated the occurrence of second cancers in a large cohort of CLL patients with particular emphasis on lung cancer and its major subtypes. We followed all patients diagnosed with CLL in Denmark in the period 1943-2003 (n = 12,373) for the occurrence of second cancers. The relative risk was expressed as the standardized incidence ratio (SIR), i.e. the ratio of observed to expected number of cancers, based on incidence rates for the Danish population. During follow-up 1,105 cancers occurred among the CLL patients (SIR = 1.59 (95% CI 1.50-1.69)). SIR for all cancers combined remained elevated more than 10 years after CLL (SIR = 1.80 (1.56-2.08)). Lung cancer occurred in 141 patients (SIR = 1.61 (1.37-1.90)). The relative risk of lung cancer did not vary by gender, or time of follow-up, but was higher in younger (SIR(<60 years) = 2.22 (1.62-3.06)) than in older (SIR(70-79 years) = 1.21 (0.88-1.68)) age-groups. Elevated risks were observed for adenocarcinoma (SIR = 2.20 (1.57-3.08)) and squamous cell carcinoma (SIR = 1.52 (1.06-2.17)) of the lung. We speculate that shared genetic risk factors may explain the accumulation of lung and other cancers in CLL patients.

Entities:  

Mesh:

Year:  2007        PMID: 17351903     DOI: 10.1002/ijc.22672

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

2.  Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study.

Authors:  Inger Lise Gade; Signe Juul Riddersholm; Ilse Christiansen; Annika Rewes; Mikael Frederiksen; Lisbeth Enggaard; Christian Bjørn Poulsen; Olav Jonas Bergmann; Dorte Balle Gillström; Robert Schou Pedersen; Linda Nielsen; Helle Højmark Eriksen; Christian Torp-Pedersen; Søren Risom Kristensen; Marianne Tang Severinsen
Journal:  Blood Adv       Date:  2018-11-13

3.  Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus.

Authors:  Joseph M Flynn; Leslie Andritsos; David Lucas; John C Byrd
Journal:  Br J Haematol       Date:  2010-03-08       Impact factor: 6.998

4.  Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Authors:  Sanford Kempin; Zhuoxin Sun; Neil E Kay; Elisabeth M Paietta; Joseph J Mazza; Rhett P Ketterling; Olga Frankfurt; David F Claxton; Joel N Saltzman; Gordan Srkalovic; Natalie S Callander; Gerald Gross; Martin S Tallman
Journal:  Acta Haematol       Date:  2019-07-23       Impact factor: 2.195

5.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

Authors:  Lindsay M Morton; Rochelle E Curtis; Martha S Linet; Elizabeth C Bluhm; Margaret A Tucker; Neil Caporaso; Lynn A G Ries; Joseph F Fraumeni
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

6.  Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer.

Authors:  Spyridon Marinopoulos; Lamprini Skorda; Stylianos Karatapanis; Antonis Rasidakis
Journal:  Med Oncol       Date:  2008-03-15       Impact factor: 3.064

7.  Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.

Authors:  C Maurer; P Langerbeins; J Bahlo; P Cramer; A M Fink; N Pflug; A Engelke; J von Tresckow; G Kovacs; S Stilgenbauer; C-M Wendtner; L Müller; M Ritgen; T Seiler; K Fischer; M Hallek; B Eichhorst
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

8.  Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.

Authors:  Clara J K Lam; Rochelle E Curtis; Graça M Dores; Eric A Engels; Neil E Caporaso; Aaron Polliack; Joan L Warren; Heather A Young; Paul H Levine; Angelo F Elmi; Joseph F Fraumeni; Margaret A Tucker; Lindsay M Morton
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

9.  Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015.

Authors:  Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara
Journal:  Cancer Epidemiol       Date:  2019-12-26       Impact factor: 2.984

10.  Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.

Authors:  Shalaka S Hampras; Frederick L Locke; Julio C Chavez; Nishit S Patel; Anna R Giuliano; Kyle Miller; Tarik Gheit; Massimo Tommasino; Dana E Rollison
Journal:  Leuk Lymphoma       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.